FDA seeks comments on updated labeling guidance for biosimilar products
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar products. The guidance would replace 2018 guidance to include recommendations for labeling interchangeable products, among other changes. The agency has approved 42 biosimilar products, including four interchangeable biosimilars.
Related News Articles
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…
Headline
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are…
Headline
The Centers for Medicare & Medicaid Services June 30 released revised guidance detailing how it will implement an Inflation Reduction Act program to…
Headline
A new AHIP report makes baseless claims that hospitals drive up specialty drug costs when in fact insurance companies drive up profits by steering patients to…
Blog
A new AHIP “report” suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that…